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Abstract
It is widely accepted that the most important ATP receptors involved in pain transmission belong to the P2X3 and P2X2/3
subtypes, selectively expressed in small diameter dorsal root ganglion (DRG) neurons. However, several types of the
metabotropic ATP (P2Y) receptors have also been found in primary afferent neurons; P2Y1 and P2Y2 receptors are
typically expressed in small, nociceptive cells. Here we review the results available on the involvement of P2Y receptors
in the modulation of pain transmission.
Abbreviations: 2-MeSADP – 2-methylthio ADP; 2-MeSAMP –2-methylthio AMP; 2-MeSATP –2-methylthio ATP;
a,b-meATP– a,b-methylene ATP; A3P5P –adenosine-3S-phosphate-5S-phosphate; ADP– adenosine 5S-diphosphate;
ADP-b-S–adenosine 5S-O-(2-thiodiphosphate); AMP–adenosine 5S-monophosphate; AR-C69931MX– N
6-(2-methyl-
thioethyl)-2-(3,3,3-trifluoropropylthio)-b,g-dichloromethylene ATP; ATP – adenosine 5S-triphosphate; BDNF–brain-derived
neurotropic factor; [Ca
2+]i–intracellular Ca
2+ concentration; CGRP–calcitonin gene-related peptide; CREB–cAMP-responsive
element binding protein; DAMGO – D-Ala
2,N-Me-Phe
4,Gly-ol
5-enkephalin; DPDPE – D-penicillamine(2,5)-enkephalin; DRG–
dorsal root ganglion; EPSP – excitatory postsynaptic potential; GDP-b-S– guanosine 5S-O-(2-thiobisphosphate);
GF109203x–PKC inhibitor; HEK–human embryonic kidney-derived; IB4–is ol ec ti nB 4;I P 3–inositol 1,4,5-triphosphate;
IR–immunoreactivity, immunoreactive; KCNQ2–potassium voltage-gated channel, KQT-like subfamily, member
2; mRNA – messenger ribonucleic acid; MRS-2179–N
6-methyl-2S-deoxyadenosine-3S,5S-bisphosphate; MRS-2279–
(1R,2S,4S,5S)-1-[(phosphato)methyl]-4-(2- chloro-6-aminopurin-9-yl) bicyclo [3.1.0]-hexane-2- phosphate; NG–nodose
ganglion; P2X–ionotropic ATP receptor; P2Y–metabotropic ATP receptor; pCREB–phosphorylated CREB; PKC–
protein kinase C; PLC–phospholipase C; PPADS–pyridoxal-phosphate-6-azophenyl-2S,4S-disulphonic acid; RB2–
reactive blue 2; RT-PCR–reverse transcription polymerase chain reaction; SGC–satellite glial cells; SP–substance P;
TG–trigeminal ganglion; TRPV1–vanilloid receptor 1; U-50488H–trans-(T-3,4-dichloro-N-methyl-N-(2-[1-pyrrolidinyl]-
cyclohexyl)- benzeneacetamide; U73122–PLC inhibitor; UDP–uridine 5S-diphosphate; UTP–uridine 5S-triphosphate;
VACC – voltage-activated calcium channel
Introduction
It was observed in the late sixties that the endogenous P2
receptor agonist adenosine 5S-triphosphate (ATP) can
evoke pain sensation [1, 2]. The most important ATP-
sensitive receptors involved in pain transmission appear to
be the ligand-gated P2X3 and P2X2/3 subtypes, selectively
expressed by a subpopulation of small diameter dorsal root
ganglion (DRG) cells binding isolectin B4 (IB4)a n d
possessing also capsaicin-sensitive vanilloid receptors
(TRPV1) [3, 4]. Numerous studies have shown that P2X
receptors play a crucial role in facilitating pain trans-
mission at peripheral and spinal sites; a large number of
reviews has recently been published on these receptors and
nociception [5–10]. However, possible roles for metabo-
tropic P2Y receptors in nociceptive signaling have received
limited attention. Here we review the results available on
P2Y receptors relating to the sensory pathway and on the
available evidence that P2Y receptors are also involved in
the modulation of pain transmission.
P2Y receptors
The following G protein-coupled P2Y receptors have been
characterized to date in humans: P2Y1,P 2 Y 11, P2Y12, and
P2Y13 (sensitive to the adenine nucleotides ADP and
ATP); P2Y4 and P2Y6 (sensitive to the pyrimidine
nucleotides UDP and UTP); P2Y2 (sensitive to both ATP
and UTP); P2Y14 (sensitive to uridine sugars such as UDP-
glucose and UDP-galactose) [11–16].
P2Y receptors, in common with other G protein-coupled
receptors, have seven transmembrane domains, an extra-
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P2Y1,P 2 Y 2,P 2 Y 4 and P2Y6 receptors are positively
coupled to phospholipase C via Gq,11 proteins, while the
P2Y12–14 receptors are negatively coupled to adenylyl
cyclase via Gi proteins. P2Y11 receptors are dually coupled
to Gq,11 and Gs proteins, activating both phospholipase C
and adenylyl cyclase [11–16].
The ligand selectivity of different P2Y receptor sub-
types has extensively been discussed elsewhere [17–19].
ADP, adenosine 5S-O-(2-thiodiphosphate) (ADP-b-S) and
2-methylthio ADP (2-MeSADP) are agonists at P2Y1,
P2Y12 and P2Y13 receptors. Among them, ADP and ADP-
b-S act also at P2X1,2,3,4 receptors. UTP is selective for
P2Y2 and P2Y4 receptors, whereas UDP preferentially
activates the P2Y6 receptor; UDP-glucose acts at P2Y14
receptors. P2Y11 receptors are activated by ATP and
2-MeSATP. Adenosine-3S-phosphate-5S-phosphate (A3P5P),
N
6-methyl-2S-deoxyadenosine-3S,5S-bisphosphate (MRS-
2179) and (1R,2S,4S,5S)-1-[(phosphato)methyl]-4-(2- chloro-
6-aminopurin-9-yl) bicyclo [3.1.0]-hexane-2- phosphate
(MRS-2279) are selective antagonists for the P2Y1 receptor.
Pyridoxal-phosphate-6-azophenyl-2S,4S-disulphonic acid
(PPADS) also shows some preference for P2Y1 receptors
over the residual P2Y receptor-types. N
6-(2-Methylthioethyl)-
2-(3,3,3-trifluoropropylthio)-b,g-dichloromethylene ATP (AR-
C69931MX) is a selective antagonist at P2Y12 and P2Y13
receptors, whereas 2-MeSAMP selectively blocks the P2Y12
receptor-type.
Expression of P2Y receptors in neurons of
sensory ganglia
In contrast to P2X3 receptors, which are mostly expressed
in small neurons of the DRG and other sensory ganglia,
P2Y receptors seem to be equally expressed in small, large
and medium-sized sensory neurons. Reverse transcription
(RT)-PCR demonstrated the presence of P2Y1 receptor
mRNA in rat DRG, nodose ganglion (NG) and trigeminal
ganglion (TG) [20–22]. In situ hybridization studies
showed the presence of P2Y1 receptor mRNA in about
20% of both rat and mouse DRG neurons [23, 24], with the
most intense staining in large, RT-97-immunoractive (IR)
neurons, and weaker staining in small, peripherin-IR
neurons [25]. Immunostaining studies showed that P2Y1
receptor antibodies stained over 80% of the DRG, NG and
TG neurons [22]. In this study, the small-diameter neurons
were stained much more intensely than the medium- and
large-diameter neurons. The staining was evenly distrib-
uted throughout the cytoplasm of these cells and immunor-
eactive cells were randomly distributed throughout the
ganglia. P2Y1 receptor-IR has also been demonstrated in
cell bodies of the rat NG [26]. Ligation of the vagus nerve
led to accumulation of staining adjacent to the ligature and
this accumulation was found central to the proximal
ligature and peripheral to the distal ligature, suggesting
anterograde and retrograde transport, respectively. These
data imply that P2Y1 receptors are transported to and
expressed functionally on terminals of sensory nerves.
The co-expession of P2Y1 mRNA with TRPV1 mRNA,
thought to be characteristic for nociceptive DRG neurons,
was investigated by in situ hybridization. Astonishingly only
2% of TRPV1 mRNA-expressing cells possessed also P2Y1
mRNA and vice versa [24]. However, in another study,
where the receptor proteins were identified by immunocy-
tochemistry in combination with confocal laser scanning
microscopy, co-staining for P2Y1,T R P V 1a n dP 2 X 3 recep-
tors was observed in 80% of small-diameter (20–35 mM)
neurons in the rat DRG [27]. These data were confirmed by
the finding that P2Y1 receptors are often co-localized on the
same cells with P2X3 receptors [22]. A high number of
P2X3-IR cells were also found to be P2Y1 receptor-IR in
DRG, NG and TG; in general, more neurons appeared to
express P2Y1 receptors than P2X3 receptors [22]. Double
immunofluorescence histochemistry showed that 30% of
P2Y1 receptor-IR cells showed also NF200-IR in DRG, NG
and TG. NF200 is an anti-neurofilament antibody that stains
the large-diameter neurons with myelinated axons [22]. The
P2Y1 receptor was also co-localized with the neuropeptide
calcitonin gene-related peptide (CGRP) in more than 60% of
DRG, NG and TG cells. The P2Y1 receptors were further
highly co-expressed in IB4 containing neurons; 80%, 60%
and 20% of the IB4 cells were also immunoreactive for the
P2Y1 receptor, in DRG, NG and TG cells, respectively [22].
RT-PCR revealed the presence of P2Y2 mRNA in rat
DRG, NG and TG [21, 22]. In situ hybridization showed
that 80% of adult rat DRG neurons expressed P2Y2 mRNA,
but only half of these neurons responded to UTP by
phosphorylating the cAMP-responsive element binding
protein (CREB) [28]. P2Y2 mRNA was expressed in
neurons of all sizes, but was seen less frequently in large
cells: 90% of small cells (G30 mm diameter) were positive,
as were 40% of larger cells (940 mm diameter). A similar
distribution of P2Y2 expression was observed in neurons of
the rat TG [28]. However, another in situ hybridization
study showed that only 20% of rat DRG neurons expressed
P2Y2 receptors and that a significant population of DRG
neurons co-expressed P2Y2 and TRPV1 mRNA [24].
RT-PCR confirmed the presence of P2Y4 mRNA in rat
DRG, NG and TG [21, 22]. Immunohistochemistry
revealed that the number of neurons staining for the P2Y4
receptor antibody was lower than that staining for the P2Y1
receptor antibody, and the medium- and large-diameter
neurons were stained much more frequently than the small-
diameter neurons [22]. The co-localization of P2Y4 and
P2X3 receptors was less frequent than that of P2Y1 and
P2Y4 receptors. Double immunofluorescence histochemis-
try showed that many P2Y4 receptor-IR cells showed also
NF200-immunoreactivity in DRG, NG and TG. CGRP-IR
cells co-expressed P2Y4 receptors much less frequently
than P2Y1 receptors. Unlike P2Y1 receptor-IR cells, P2Y4-
IR neurons lacked IB4 in these sensory ganglia [22].
Considering these findings, it is likely that P2Y4 receptors
are preferentially expressed in large, IB4- and CGRP-
negative DRG neurons. These neurons are known to be
implicated in the transmission of tactile allodynia but not
acute pain or thermal hyperalgesia [29] suggesting that
P2Y4 receptors may play a role in this process.
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DRG, NG and TG, but the receptor was not confined to
sensory neurons [21, 22]. ATP-induced Ca
2+-release from
inositol 1,4,5-triphosphate (IP3)-sensitive Ca
2+ stores in
large (30–45 mM) but not in small (20–25 mM) mouse
DRG neurons [30]. The effect was thapsigargin-sensitive;
however, the involvement of P2Y receptor subtypes other
than P2Y6 was not investigated. In another functional study,
UTP caused an increase of intracellular calcium concentra-
tion ([Ca
2+]i) in equal numbers of small (G30 mM), medium
(30–40 mM) and large cells (940 mM), suggesting the
existence of P2Y2 and/or P2Y4 receptors at these neurons
[21]. ADP-b-S evoked Ca
2+ release from intracellular stores
of small (20–35 mM) and IB4-IR (nociceptive) DRG cells
from the rat and this effect was antagonized by the P2Y1
receptor antagonist MRS 2179 [31]. ATP, ADP and UTP
were shown to inhibit voltage-activated calcium channels
(VACCs) in cultured small-diameter (20–35 mM) DRG
neurons from the rat, indicating the functional presence of
P2Y1,P 2 Y 2 and/or P2Y4 receptors on these cells [27].
P2Y receptors in neurons of the dorsal spinal cord
There are only few and relatively controversial data
available on the presence of P2Y receptors at dorsal horn
neurons. It has been concluded that ATP increases [Ca
2+]i
in 30% of these neurons via P2Y receptor activation, since
the selective P2X1,3 receptor agonist a,b-methylene ATP
(a,b-meATP) had no effect [32]. However, ATP also acts
via ionotropic P2X receptors of the P2X2,4,6 types which
have been shown to be expressed on the somata of dorsal
horn neurons [7]. The involvement of these receptors in
ATP-induced [Ca
2+]i transients was not excluded by
selective pharmacological ligands or omission of Ca
2+
from the extracellular solution. In another study, the P2Y-
selective 2-MeSADP caused no change in [Ca
2+]i in spinal
cord cultured neurons [33]. The non-selective P2 agonists
ATP and 2-MeSATP increased [Ca
2+]i in 60% of neurons
[34]. The response was not abolished in Ca
2+-free
extracellular solution, and PPADS blocked the effect of
2-MeSATP. The possible influence of glutamate, released
from neighboring cells, was ruled out using diverse
glutamate receptor antagonists. In acutely isolated neurons
which lost their dendrites, there was no P2Y response [34].
However, further experiments are needed to reliably
evaluate the expression of P2Y receptors on spinal cord
dorsal horn neurons (Figure 1).
P2Y receptors in glial cells
Sensory ganglia contain, in addition to neurons, glial cells
that wrap around the neurons. These cells, also called
Figure 1. The role of P2Y receptors in pain pathways. The P2Y receptors are present on DRG cells, spinal cord astrocytes and probably on dorsal horn
neurons. In DRG neurons, the P2Y1 receptor stimulates the plasma membrane Ca
2+ pump which removes Ca
2+ from the cell. The P2Y1 receptor further inhibits
VACCs, which play a role in the vesicular release of glutamate from DRG neurons. The P2Y2 receptor potentiates capsaicin-induced membrane currents
through the vanilloid receptor 1 (TRPV1), increases the axonal transport of membrane-bound organelles and activates the phosphorylation of CREB in DRG
cells. P2Y receptors of unidentified subtypes inhibit the M-type potassium currents through KCNQ channels in DRG cells and potentiate the capsaicin-induced
release of CGRP from these cells. Of course, P2X3 and P2X2/3 receptors are also present at the terminals of DRG neurons. P2X3 receptors have been shown to
positively modulate the release of glutamate, while P1 receptors of the A1-subtype depress glutamate release. Dorsal horn astrocytes are known to release ATP
which is in turn able to activate neighboring cells via P2Y1 and P2Y2 receptors. Finally, spinal cord neurons are endowed with P2X2,4,6 and ionotropic
glutamate receptors. The presence of P2Y receptors appears to be likely but has not been confirmed yet. ATP: adenosine-5S-triphosphate; CGRP: calcitonin
gene-related peptide; CREB: cAMP-responsive element binding protein; DRG: dorsal root ganglion; Glu: glutamate; GluR: glutamate receptor; KCNQ:
potassium voltage-gated channel; pCREB: phosphorylated CREB; PKC: protein kinase C; VACC: voltage-activated calcium channel.
P2Y receptors and pain 5satellite glial cells (SGCs), are closely apposed to the
neurons [35]. There is histological evidence that SGCs are
affected in animal models for pain [36–39]. Specific P2Y
receptor agonists (UTP, 2-MeSADP and ADP-b-S) but not
the specific P2X1,3 receptor agonist a,b-meATP caused an
increase in intracellular Ca
2+ concentration in SCGs,
indicating the functional presence of P2Y1 and P2Y2 or
P2Y4 receptors on these cells [40].
ATP, ADP, 2-MeSATP and 2-MeSADP all increased
[Ca
2+]i in almost all astrocytes and in 20% of oligoden-
drocytes from cultured dorsal horn, whereas a,b-meATP
had no effect [32, 33]. The action of the different P2Y1
receptor agonists were independent of extracellular Ca
2+
and sensitive to suramin, A3P5P and thapsigargin, indicat-
ing that these cells possess functional P2Y1 receptors. In
one of these studies, RT-PCR revealed the presence of
P2Y1 mRNA in the spinal cord [33]. Since 2-MeSADP
caused no change in [Ca
2+]i of spinal cord neurons, it was
concluded that the astrocytes are the source of P2Y1
mRNA detected in the whole tissue. UTP was also shown
to be able to increase [Ca
2+]i, although only in 30% of
astrocytes from the dorsal horn [41]. The UTP-induced
Ca
2+ responses were thapsigargin-sensitive, pertussis toxin-
insensitive, and both PPADS and suramin could antagonize
them, demonstrating the functional expression of P2Y2
receptors in dorsal horn astrocytes. Both the P2Y1 and
P2Y2 receptors were found to be linked via G protein
coupling to the release of [Ca
2+]i via the phospholipase C
(PLC)/IP3 pathway [42].
There are only sparse data available on the expression of
P2Y receptors in spinal cord microglia. Application of the
P2X/P2Y agonists ATP and 2-MeSATP on cultured
microglia from rat spinal cord in the absence of extrac-
ellular Ca
2+ induced an increase in [Ca
2+]i, whereas the
P2X1,3,4-selective b,g-MeATP had no effect [43]. There-
fore, ATP and 2-MeSATP may have increased [Ca
2+]i by
activating a hitherto uncharacterized P2Y receptor-type.
P2Y receptors and pain
Excitation of DRG cells; possible noxious effects
In an early study on bullfrog DRG, ATP inhibited the
M-type potassium current (Figure 1), leading to depolariza-
tion and initiation of action potentials [44]. Intracellularly
applied guanosine 5S-O-(2-thiobisphosphate) (GDP-b-S),
an inhibitor of G protein-mediated reactions, prevented the
effect of ATP, suggesting the involvement of P2Y recep-
tors. The M-current is a low-threshold, non-inactivating,
voltage-sensitive K
+ current, which is weak or undetectable
at resting membrane potential and increases with mem-
brane depolarization, inducing spike frequency adaptation
and acting as a dynamic brake on neuronal excitability
[45, 46]. M-currents emerge from homo- and hetero-
multimeric assemblies of KCNQ2-5 protein subunits [47].
Considering that agonists of M-currents have been shown
to be antinociceptive [48], P2Y receptors inhibiting these
currents may be able to stimulate the pain transmission.
In human embryonic kidney-derived HEK-293 cells,
ATP, ADP, 2-MeSATP and UTP potentiated the capsaicin-
evoked inward currents (Figure 1) [20]. PPADS, reactive
blue 2 (RB2) and the protein kinase C (PKC) inhibitor
calphostin C inhibited the stimulatory effect of ATP.
Moreover, ATP treatment lowered the threshold temper-
ature for TRPV1 activation from 42 to 35 -C, suggesting
that TRPV1 activation could trigger the sensation of pain at
normal body temperature in the presence of ATP. In further
experiments on cultured rat DRG neurons, ATP and ADP
caused the same potentiation of TRPV1 as on HEK-293
cells. This effect was independent of P2X receptors, since
in cells with P2X receptor-mediated transient currents the
magnitude of ATP-induced potentiation of capsaicin-
evoked currents was indistinguishable from that seen in
neurons lacking P2X responses. A following study from
the same group revealed the importance of P2Y2 receptors
in nociception through TRPV1 [24]. It was reported that
ATP-induced thermal hyperalgesia in vivo is abolished in
mice lacking TRPV1, whereas it is preserved in P2Y1
receptor-deficient mice. Moreover, patch-clamp analyses
using mouse DRG neurons indicated the involvement of
P2Y2 rather than P2Y1 receptors. The potentiation of
capsaicin-evoked currents through ATP was still observed
in P2Y1-deficient mice, and UTP also potentiated TRPV1
in these cells. Suramin, which blocks P2Y2 but not P2Y4,
abolished the effect of UTP.
ATP, but not UTP, accelerates Ca
2+ efflux from rat DRG
cells by stimulating the plasma membrane Ca
2+ pump
(Figure 1) [49]. Ca
2+ entering the cell during excitation
must be removed from the cytoplasm to maintain normal
Ca
2+ homeostasis; the plasma membrane Ca
2+ pump is a key
component of the Ca
2+ extrusion machinery in neurons [50].
The stimulatory effect of ATP was prevented by PPADS,
the P2Y1 antagonist A3P5P, the phospholipase C inhibitor
U73122 and by inhibition of PKC through GF109203x.
This acceleration of the plasma membrane Ca
2+ pump via
P2Y1 receptors caused a decrease in amplitude and
duration of the action potential after-hyperpolarization
and thereby an increase in the excitability of DRG cells.
UTP evoked a slow-onset depolarization and sustained
firing in dissociated DRG neurons from the rat that
persisted for tens of seconds after removal of UTP from
the medium [28]. In a subsequent study, UTP activated
sustained action potential firing in 50% of C fibers using
the skin nerve preparation from the adult mouse [51]. UDP
had no effect, pharmacologically excluding the involve-
ment of P2Y6 receptors. The majority (70%–80%) of UTP-
sensitive C- and AM fibers respond strongly to capsaicin,
whereas UTP-insensitive fibers were largely capsaicin-
insensitive. Most of the UTP-sensitive C- and AM fibers
(80%–100%) also responded to the P2X agonist a,b-
meATP, indicating that P2Y and P2X receptors are widely
co-expressed on these fibers. These data also support the
idea that P2Y2 receptors on the terminals of capsaicin-
sensitive and P2X3-expressing cutaneous sensory neurons
effectively stimulate nociceptive transmission [51].
Furthermore, UTP and ATP, but not the P2Y1,12,13 pref-
erential ADP, increased phosphorylation of the transcrip-
6 Z. Gerevich & P. Illestion factor CREB in 40% of the DRG neurons (Figure 1),
in a PLC-dependent way [28]. Phosphorylated CREB
(pCREB) is known to induce the expression of numerous
neuropeptides (CGRP, substance P [SP] and brain-derived
neurotropic factor [BDNF]) that are upregulated in sensory
neurons in response to injury or inflammation [52–54].
Ninety-five percent of the pCREB-IR neurons also dis-
played peripherin staining, indicating that DRG neurons
with unmyelinated axons are involved. One-third of these
cells also expressed CGRP and 40% IB4. These data
suggest that UTP evokes CREB phosphorylation in a
subset of nociceptive DRG neurons. The UTP-induced
phosphorylation of CREB was inhibited by suramin, but
not by cibacron blue, an antagonist of P2Y4 but not of
P2Y2 receptors, indicating an action via P2Y2 receptors. It
seems likely that P2Y2 receptors, increasing the excitabil-
ity of sensory neurons in the short term, may also activate a
transcription factor that is likely to foster the expression of
nociceptive neurotransmitters in the long term.
UTP has been shown to stimulate CGRP release from rat
DRG neurons in the absence of extracellular Ca
2+, and
suramin abolished this stimulatory action [21]. These data
suggest that P2Y2 receptor activation and the subsequent
increase of [Ca
2+]i may be accompanied by the release of
the neuropeptide CGRP from the first order sensory
neurons stimulating pain transmission. In contrast, in a
more detailed study, neither ATP, UTP nor 2-MeSATP
increased the basal release of SP or CGRP from cultured
embryonic rat DRG neurons [55]. However, the concen-
tration of UTP used in this study was lower than that used
by Sanada et al. [21] (10 vs 100 mM) which can explain the
inconsistency between the results. Similarly, ATP had little
direct stimulatory effect on the release of CGRP from the
nerve terminals in isolated rat dura mater but augmented
proton-induced release of CGRP [56]. In embryonic rat
DRG neurons, the ability of P2Y receptor agonists to
modulate the excitability to capsaicin was also investigated
[55]. ATP and UTP, but not 2-MeSATP or a,b-meATP,
augmented the release of SP and CGRP evoked by
capsaicin (Figure 1). The sensitizing effect of ATP was
antagonized by suramin but not by PPADS and was
inhibited by the PKC inhibitor bisindolylmaleimide.
Together, these data suggest that ATP, acting at P2Y
receptors in sensory neurons, can augment their sensitivity
to other stimuli in a PKC-dependent manner.
ATP and UTP also increased axonal transport of mem-
brane-bound organelles in anterograde and retrograde di-
rections in cultured adult mouse DRG neurons (Figure 1);
suramin completely blocked this effect of ATP [57]. ADP,
a,b-meATP and 2-MeSATP were ineffective, suggesting
the involvement of P2Y2 receptors. Synaptic functions
including neurotransmitter release and up-/downregulation
of receptors require axonal transport [58, 59]. In primary
sensory neurons from the rat DRG, axonal transport
delivers receptors, ion channels, sensory neuropeptides,
glutamate and aspartate in both central and peripheral
directions [59]. It was suggested that blockade of axonal
transport can inhibit the development of neuropathic pain
by blocking the signaling of peripheral injury to the central
neurons [60]. In this case, P2Y2 receptor activation through
agonists would be pronociceptive through stimulation of
the axonal transport.
There are several lines of evidence indicating that spinal
cord glial cells can create and maintain exaggerated pain
states [61–63]. These cells become activated in response to
substances released by both the primary afferent terminals
(ATP, SP, CGRP, and glutamate) and by spinal cord
neurons (nitric oxide, prostaglandins). It is well known that
the ATP-induced activation of glial cells is mediated by
both P2X and P2Y receptors [64, 65]. Once activated, glial
cells can release a variety of neurotransmitters and neuro-
modulators including ATP, which in turn can further
stimulate neighboring glial cells and neurons, and is
capable of altering pain transmission. This effect is due
both to an enhanced release of SP and glutamate from the
central terminals of DRG neurons [66, 67] and to an
increased excitability of spinal cord neurons [63]. One
important way by which astrocytes regulate their own
activity is via Ca
2+ signals. A rise in [Ca
2+]i limited to one
part of an astrocyte may propagate within the rest of the
cell, and Ca
2+ responses can be transmitted from one
astrocyte to others leading to Ca
2+ waves that spread within
astrocyte networks [68]. There are two main routes by
which Ca
2+ waves can propagate from one cell to another:
Through gap junction channels [69] and through the
extracellular space involving the release of pharmacolog-
ically active substances from one cell activating surface
receptors on neighboring cells. A growing body of
evidence indicates that a principal mechanism for the
propagation of Ca
2+ waves between astrocytes is by release
of ATP, which acts as a diffusible extracellular messenger
[70–72]. Release of ATP from astrocytes during Ca
2+ wave
propagation has been demonstrated [72]. In spinal cord
astrocytes, Ca
2+ wave propagation was found to be me-
diated by P2Y1 and P2Y2 receptors (Figure 1) [33, 73].
Both receptors were necessary and sufficient for the propa-
gation of Ca
2+ waves but characteristics of the propagation
were different: Ca
2+ waves propagating via P2Y2 receptors
travel faster and further than those propagating via P2Y1
receptors. It was suggested that mediation of Ca
2+ waves
by ATP leading to activation of two subtypes of receptor,
P2Y1 and P2Y2, may be a general principle for gliotrans-
mission in the central nervous system [73].
Antinociceptive effects
P2Y receptor agonists were found to inhibit cytokine
release from activated spinal cord microglia [43]. The
rank order of inhibitory potency on cytokine release was:
2-MeSATP = ATP 9 ADP-b-S = ADP d UTP 9 UDP.
However, P2Y antagonists or further P2X and P2Y
selective substances were not used in this study. It is
known that activated microglia and astrocytes in the spinal
cord can create and maintain chronic pain states [61, 74].
P2Y receptors inhibiting microglia overstimulation through
the reduction of cytokine release from these cells could
interrupt chronic pain development and continuation.
P2Y receptors and pain 7Repetitive stimulation of the dorsal root, with an
intensity adequate to activate C-fibers but not A-fibers,
induced slow depolarization of substantia gelatinosa neu-
rons in the adult rat spinal cord transverse slices with
dorsal root attached [75]. This effect was inhibited by the
m-opioid receptor agonist DAMGO, but not by DPDPE and
U-50488H, d- and k-opioid agonists, respectively, indicat-
ing that the repetitive stimulation of C-fibers of the dorsal
root is relevant to spinal nociception. ATP and UTP, but
not a,b-meATP, were found to inhibit the slow depolariza-
tion of the substantia gelatinosa neurons in the dorsal horn
[76]. The inhibitory effect of ATP was not reversed by
suramin, the only antagonist used in this study.
In a subsequent study from the same laboratory, UTP and
UDP were shown to be analgesic when applied intrathecally
(i.t.) to rats [77]. In the paw pressure test using normal rats,
i.t. administration of UTP and UDP elevated the mechan-
ical nociceptive threshold, whereas ATP and a,b-meATP
lowered it. Similarly, in the tail-flick test, UTP and UDP
prolonged the thermal nociceptive latency. In the von Frey
filament test on rats, while ATP induced a significant and
long-lasting tactile allodynia, UTP and UDP were ineffec-
tive. In the neuropathic pain model, in which the sciatic
nerves of rats were partially ligated, UTP and UDP were
found to be antiallodynic. Furthermore, UTP and UDP
caused no motor deficit in the inclined plane test,
indicating that the elevation of mechanical nociceptive
threshold and prolongation of the thermal nociceptive
latency were likely due to antinociceptive effects, rather
than deficits of motor function. Taken together, i.t.
administration of UTP and UDP had antinociceptive
effects on acute mechanical and thermal nociception in
normal rats via P2Y2,P 2 Y 4, and P2Y6 receptors. The
mechanism underlying these effects was not investigated.
In addition to the pyrimidine nucleotides acting on P2Y2,
P2Y4, and P2Y6 receptors, the ADP analog ADP-b-S has
also been found to cause analgesia [27]. ADP-b-S, applied
intrathecally to rats, prolonged the nociceptive threshold in
the tail-flick test. Furthermore, in the same study, the
possible mechanism of action was also investigated and
ATP was found to inhibit the N-type VACCs and the sub-
sequent increase in [Ca
2+]i in rat DRG neurons (Figure 1).
No other Ca
2+ channel types were altered. This effect of
ATP was antagonized by the P2Y1 selective antagonists
MRS 2179 and PPADS and was abolished by intracellular
application of GDP-b-S, a competitive G protein inhibitor,
suggesting the participation of P2Y1 receptors. Investiga-
tion of the secondary messenger pathway revealed that the
inhibition was mediated through the bg subunit of the G
protein, since a strongly depolarizing pre-pulse applied
shortly prior to the test pulse and known to dissociate Gbg
from the VACC prevented the inhibitory effect of ATP.
Furthermore, ADP-b-S inhibited the dorsal root-evoked
polysynaptic population EPSPs in the hemisected spinal
cord from rats, indicating that the site of action of the P2Y1
receptors is the central terminal of the DRG cells. It is
known that N-type calcium channels play a major role in
the release of neurotransmitters and ADP, which is
generated by the enzymatic degradation of ATP, may
inhibit these channels through P2Y1 receptors resulting in
decreased sensory transmitter (glutamate) release at the
central terminals and as a consequence in reduced spinal
pain transmission.
In the same study, UTP was also tested and was found to
inhibit the VACCs [27], suggesting that the analgesic
effect of UTP [77] may be mediated by the same
mechanism as that of ADP-b-S. It is interesting to note
that in vitro UTP has also been found to excite DRG
neurons (see above). Hence, these opposing effects of UTP
may finally lead to an inhibition of pain transmission.
Conclusion
The demonstration of P2Y receptor gene expression in
sensory cells and the presence of functional receptors on
the cell surface suggests that these receptors can play a role
in the nociceptive transmission. Co-localization of the
different P2Y receptor-subtypes with markers for nocicep-
tive neurons showed that the P2Y1 and P2Y2 receptors are
typically expressed in small, nociceptive cells, whereas the
P2Y4 subtype seems to be present in large neurons
involved in the transmission of tactile allodynia. Spinal
cord astrocytes known to play a significant role in the
modulation of pain transmission also express functional
P2Y1 and P2Y2 receptors. The investigation of different
P2Y receptor agonists acting selectively on the P2Y1 or
P2Y2/4 subtypes showed that these receptors can both
stimulate and inhibit the excitability of sensory neurons
without significant subtype specificity. On the other hand,
in vivo studies revealed that i.t. administration of the P2Y2/
4 agonist UTP and of the P2Y1 agonist ADP-b-S inhibits
pain transmission. It was suggested that P2Y receptors
inhibit the release of glutamate from the central terminal of
the DRG neurons via inhibition of the VACCs.
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